Sutimlimab (Enjaymo)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

Anti-C1s antibody

Diseases for which it is used

History of changes in FDA indication

  • 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)

Also known as

  • Code name: BIVV009
  • Generic name: sutimlimab-jome
  • Brand name: Enjaymo
Retrieved from "https://hemonc.org/w/index.php?title=Sutimlimab_(Enjaymo)&oldid=63788"